Lupin has received a warning letter from the USFDA for the Company’s Tarapur, Maharashtra (India) facility. The USFDA had inspected the Lupin Tarapur site from March 22, 2022 to April 4, 2022. The Company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility.
The company is committed to addressing the concerns raised by the USFDA and will work with the USFDA to resolve these issues at the earliest. The company upholds quality and compliance issues with utmost importance and remain committed to be compliant with CGMP quality standards across all its facilities.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
